Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HYRNUO vs APOKYN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
(E)-2-(((2-(6,7-dimethoxyquinazolin-4-ylamino)phenyl)thio)methyl)-4-methyl-2H-pyrazolo[1,5-a]pyrazin-3(5H)-one is a selective inhibitor of fibroblast growth factor receptor (FGFR) 1, 2, 3, and 4. It binds to the ATP-binding site of FGFR kinases, blocking downstream signaling pathways, including RAS-MAPK-ERK and PI3K-AKT, thereby inhibiting tumor cell proliferation and angiogenesis.
Apomorphine is a non-ergoline dopamine agonist that stimulates dopamine D2 and D1 receptors. It also activates D3, D4, and D5 receptors and has some serotonergic and adrenergic activity.
Treatment of adult patients with previously treated, unresectable locally advanced or metastatic urothelial carcinoma (UC) with FGFR3 genetic alterations,Treatment of adult patients with unresectable locally advanced or metastatic cholangiocarcinoma (CCA) with FGFR2 gene fusions or other rearrangements
Treatment of acute, intermittent hypomobility episodes (off episodes) in patients with advanced Parkinson's disease
100 mg orally once daily
Subcutaneous injection: 0.2 m L (2 mg) as a test dose, then 0.1-0.6 m L (1-6 mg) as needed for episodes of hypomobility; maximum single dose: 0.6 m L (6 mg); maximum daily dose: 2.0 m L (20 mg).
Terminal elimination half-life is 12-15 hours in adults with normal renal function, supporting twice-daily dosing.
Terminal elimination half-life approximately 30–60 minutes (range 0.5–1 hour); clinically, rapid clearance necessitates continuous or frequent dosing for sustained effect
Primarily metabolized by CYP2C9 and CYP3A4; minor contributions from CYP2C19 and CYP2D6. Forms active metabolites M1 (desmethyl) and M2 (N-oxide).
Primarily hepatic via N-demethylation to norapomorphine; also undergoes sulfation and glucuronidation. CYP enzymes involved include CYP2B6, CYP2C19, and CYP3A4.
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 30% (including metabolites), with the remainder eliminated via minor metabolic pathways.
Renal (approx. 90% as metabolites and unchanged drug; <5% unchanged in urine); biliary/fecal (minor, <10%)
98% bound primarily to albumin.
Approximately 99% bound to plasma proteins (primarily albumin)
0.3-0.4 L/kg, indicating distribution into total body water with limited tissue binding.
Approximately 1.5–2 L/kg (wide distribution, extensive tissue binding)
Oral: 85% (fasting); 60% with high-fat meal (reduced absorption).
Subcutaneous injection: approximately 100% (complete absorption); oral: negligible (<2%) due to extensive first-pass metabolism; intravenous: 100%
GFR ≥60 m L/min: No adjustment. GFR 30-59: 50 mg once daily. GFR <30: Not recommended.
No specific dose adjustment recommended; use with caution in renal impairment. Data for GFR-based modifications are insufficient.
Child-Pugh A: No adjustment. Child-Pugh B: 50 mg once daily. Child-Pugh C: Not recommended.
No specific dose adjustment recommended; use with caution in moderate to severe hepatic impairment (Child-Pugh B or C).
Not established for patients under 18 years.
Not established; safety and efficacy in pediatric patients have not been studied.
No specific dose adjustment; monitor renal function and consider age-related decline.
No specific dose adjustment; elderly patients may be more sensitive to adverse effects; initiate at low end of dosing range.
None
None
Retinal pigment epithelial detachment (RPED) and other visual disturbances: conduct ophthalmic examinations prior to and during treatment,Hyperphosphatemia: monitor serum phosphate levels and manage with phosphate-lowering therapy or dose modification,Non-healing corneal ulcers: requires ophthalmologic evaluation,Embryo-fetal toxicity: can cause fetal harm; advise effective contraception
Cardiovascular effects: severe hypotension, syncope, bradycardia, and QT prolongation; monitor blood pressure and ECG,Nausea and vomiting: almost universal; pre-treatment with antiemetic (e.g., trimethobenzamide) required,Falling asleep during activities of daily living: risk of sudden sleep onset,Psychiatric effects: hallucinations, confusion, psychosis; may exacerbate existing disorders,Dyskinesias: may be precipitated or worsened,Impulse control disorders: compulsive behaviors reported,Hemolytic anemia: rare but severe risk; monitor blood counts,Skin reactions: injection site reactions, panniculitis, and pain
Concurrent use with strong CYP2C9 or CYP3A4 inducers,Pregnancy and lactation
Concurrent use of 5-HT3 antagonists (e.g., ondansetron, granisetron),Hypersensitivity to apomorphine or any component of the product,Concomitant use of drugs that prolong QT interval
No specific food interactions. Grapefruit juice does not significantly affect HYRNUO metabolism. Maintain consistent vitamin K intake if on warfarin; not applicable to HYRNUO. Alcohol may increase bleeding risk; advise moderation.
Avoid high-protein meals as they may delay absorption; take on an empty stomach for consistent response. No specific food contraindications.
HYRNUO is contraindicated in pregnancy due to demonstrated teratogenicity in animal studies and limited human data. First trimester exposure is associated with major congenital malformations including neural tube defects and cardiovascular anomalies. Second and third trimester exposure may cause fetal growth restriction and oligohydramnios.
Apomorphine is classified as Pregnancy Category C. In animal studies, maternal toxicity and fetal effects (reduced fetal weight, delayed ossification) were observed at doses ≥3 mg/kg/day (approximately 0.3 times the maximum recommended human dose). No adequate and well-controlled studies exist in pregnant women. For first trimester: potential risk based on animal data; second and third trimesters: unknown risk. Use only if potential benefit justifies potential risk to fetus.
No data available on excretion into breast milk or effects on the breastfed infant. M/P ratio unknown. Due to potential for serious adverse reactions, breastfeeding is not recommended during treatment and for at least 2 weeks after the last dose.
It is not known if apomorphine is excreted in human milk. No M/P ratio available. Due to potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account importance of drug to mother.
No established safe dose in pregnancy. Drug should not be used. If accidental exposure occurs, pharmacokinetic changes in pregnancy (increased volume of distribution, altered hepatic metabolism) may require dose adjustment, but no specific recommendations exist.
No established dosing adjustments for pregnancy. Pharmacokinetic changes during pregnancy (increased volume of distribution, renal clearance) may reduce drug exposure; however, no dose adjustment guidelines are available. Individualize based on clinical response and tolerability.
HYRNUO is a novel oral anticoagulant with high specificity for factor Xa. Monitor renal function prior to initiation and periodically; adjust dose if Cr Cl <30 m L/min. No routine coagulation monitoring required. Reversal agent andexanet alfa is available for life-threatening bleeding. Avoid in patients with mechanical heart valves or moderate-to-severe mitral stenosis. Caution with dual antiplatelet therapy due to increased bleeding risk.
Administer with an antiemetic (e.g., trimethobenzamide) to prevent severe nausea/vomiting. Use extreme caution in patients with prolonged QT interval. Injection sites must be rotated; do not inject into areas with bruising, redness, or hard lumps. Onset of effect is within 10 minutes but duration is short (about 1 hour). Monitor for orthostatic hypotension and dyskinesias.
Take HYRNUO exactly as prescribed, usually once daily with or without food.,Do not skip doses; if a dose is missed, take it as soon as remembered on the same day. Do not double the next dose.,Inform all healthcare providers that you are taking HYRNUO, especially before surgery or dental procedures.,Watch for signs of bleeding: unusual bruising, prolonged bleeding from cuts, pink/brown urine, red/black stools, coughing up blood, or vomiting blood.,Avoid aspirin, NSAIDs, or other blood thinners unless prescribed by your doctor.,Keep a list of all medications and supplements you take, as some may interact with HYRNUO.,Store at room temperature away from moisture and heat. Do not stop taking without consulting your doctor.
Take exactly as prescribed; do not use more often than directed.,Administer only into the abdomen, thigh, or upper arm; rotate injection sites.,Do not inject into areas with broken, bruised, or red skin.,Avoid driving or operating machinery until you know how the drug affects you.,Rise slowly from sitting or lying to reduce dizziness.,Report severe nausea, vomiting, hallucinations, or compulsive behaviors immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HYRNUO vs APOKYN, answered by our medical review team.
HYRNUO is a Dopamine Agonist (Antiparkinsonian) that works by (E)-2-(((2-(6,7-dimethoxyquinazolin-4-ylamino)phenyl)thio)methyl)-4-methyl-2H-pyrazolo[1,5-a]pyrazin-3(5H)-one is a selective inhibitor of fibroblast growth factor receptor (FGFR) 1, 2, 3, and 4. It binds to the ATP-binding site of FGFR kinases, blocking downstream signaling pathways, including RAS-MAPK-ERK and PI3K-AKT, thereby inhibiting tumor cell proliferation and angiogenesis.. APOKYN is a Dopamine Agonist that works by Apomorphine is a non-ergoline dopamine agonist that stimulates dopamine D2 and D1 receptors. It also activates D3, D4, and D5 receptors and has some serotonergic and adrenergic activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HYRNUO and APOKYN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HYRNUO is: 100 mg orally once daily. The standard adult dose of APOKYN is: Subcutaneous injection: 0.2 m L (2 mg) as a test dose, then 0.1-0.6 m L (1-6 mg) as needed for episodes of hypomobility; maximum single dose: 0.6 m L (6 mg); maximum daily dose: 2.0 m L (20 mg).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HYRNUO and APOKYN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HYRNUO is classified as Category C. HYRNUO is contraindicated in pregnancy due to demonstrated teratogenicity in animal studies and limited human data. First trimester exposure is associated with major congenital mal. APOKYN is classified as Category C. Apomorphine is classified as Pregnancy Category C. In animal studies, maternal toxicity and fetal effects (reduced fetal weight, delayed ossification) were observed at doses ≥3 mg/. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.